Neuroendocrine Tumors (NETs) Market Insights, Epidemiology and Market Forecast, 2016-2027

DUBLIN–(BUSINESS WIRE)–The “Neuroendocrine
Tumors (NETs) – Market Insights, Epidemiology and Market Forecast”

drug pipelines has been added to’s

The market of Neuroendocrine Tumors in 7MM was found to be USD 3.45
billion in 2016

The Neuroendocrine Tumors (NETs) – Market Insights, Epidemiology and
Market Forecast-2027′ report delivers an in-depth understanding of the
disease, historical forecasted epidemiology as well as the market
trends of NETs in the United States, EU5 (Germany, Spain, Italy, France
and United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs
having the potential to get launched in the forecast period, market
share of the individual therapies, current and forecasted market size of
Neuroendocrine Tumors from 2016 to 2027 segmented by seven major
markets. The report also covers current treatment practice/algorithm,
market drivers, market barriers and unmet medical needs to curate best
of the opportunities and assess underlying potential of the market.

Neuroendocrine Tumors Market Outlook

The Neuroendocrine Tumors market outlook of the report helps to build
the detailed comprehension of the historic, current and forecasted trend
of the market by analyzing the impact of current therapies on the
market, unmet needs, drivers and barriers and demand of better

This segment gives a through detail of market trend of each marketed
drug and late-stage pipeline therapy by evaluating their impact based on
annual cost of therapy, inclusion and exclusion criteria, mechanism of
action, compliance rate, growing need of the market, increasing patient
pool, covered patient segment, expected launch year, competition with
other therapies, brand value, their impact on the market and view of the
key opinion leaders. The calculated market data are presented with
relevant tables and graphs to give a clear view of the market at first

Key Topics Covered:

1. Key Insights

2. Neuroendocrine Tumors Epidemiology Overview at a Glance

  • Market (%) Distribution of Neuroendocrine Tumors in 2017
  • Market (%) Distribution of Neuroendocrine Tumors in 2027

3. Disease Background and Overview: Neuroendocrine Tumors (NET)

  • Introduction
  • Classification of Neuroendocrine Tumors
  • Causes
  • Risk Factors
  • Symptoms
  • Pathophysiology
  • Diagnosis
  • Grading of NETs
  • Staging of NETs

4. Epidemiology and Patient Population

  • Key Findings
  • 7MM Total Prevalent Patient Population of NETs
  • Total Incident Patient Population of NETs
  • Country Wise-Epidemiology of NETs
  • United States
  • EU5 Countries
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan

5. Treatment Algorithm

6. Unmet needs

7. Marketed drugs

  • Afinitor (Everolimus): Novartis
  • Sutent (Sunitinib Malate): Pfizer
  • Somatuline Depot (Lanreotide): Ipsen Biopharmaceuticals Inc.
  • Lutathera (lutetium Lu 177 dotatate): Advanced Accelerator
    Applications S.A.

8. Emerging drugs

9. Key Cross Competition

  • Iobenguane I-131: Progenics Pharmaceuticals
  • 177Lu-edotreotide PRRT: ITM Isotopen Technologien Muenchen
  • AMG 479: Amgen
  • Anlotinib: Advenchen Laboratories
  • Carfilzomib: Amgen
  • ATG-008: Antengene
  • Entrectinib: Ignyta
  • Fosbretabulin: Mateon Therapeutics
  • Ipilimumab: Bristol-Myers Squibb
  • Ribociclib: Novartis
  • Pembrolizumab: Merck
  • RRx-001: EpicentRx
  • Axitinib: Pfizer
  • Cabozantinib: Exelixis
  • CAM2029: Camurus
  • Atezolizumab and Bevacizumab: Genentech
  • Lenvatinib: Eisai
  • Pasireotide LAR: Novartis
  • Spartalizumab: Novartis
  • Tirapazamine: Teclison
  • Pentarin: Tarveda Therapeutics
  • Sulfatinib: Hutchison MediPharma
  • Ibrutinib: Pharmacyclics
  • Ramucirumab: Eli Lilly
  • ALT 803: Altor Biosciences
  • Talimogene laherparepvec: Amgen
  • Netazepide: Trio Medicines

10. Neuroendocrine Tumors: 7 Major Market Analysis

  • Key Findings
  • Market Size of Neuroendocrine Tumors (NETs) in 7MM
  • Market Outlook by Country

11. Market Drivers

12. Market Barriers

13. Appendix

Companies Mentioned

  • Advanced Accelerator Applications S.A.
  • Advenchen Laboratories
  • Altor Biosciences
  • Amgen
  • Antengene
  • Bristol-Myers Squibb
  • Camurus
  • Eisai
  • Eli Lilly
  • EpicentRx
  • Exelixis
  • Genentech
  • Hutchison MediPharma
  • Ignyta
  • Ipsen Biopharmaceuticals Inc.
  • ITM Isotopen Technologien Muenchen
  • Mateon Therapeutics
  • Merck
  • Novartis
  • Novartis
  • Pfizer
  • Pharmacyclics
  • Progenics Pharmaceuticals
  • Tarveda Therapeutics
  • Teclison

For more information about this drug pipelines report visit